Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
Conference organizers are taking steps to protect attendees from COVID-19, but some oncology professionals think more needs to be done.